| Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial AH Røssevold, NK Andresen, CA Bjerre, B Gilje, EH Jakobsen, SX Raj, ... Nature Medicine 28 (12), 2573-2583, 2022 | 59 | 2022 |
| ICON: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer JA Kyte, NK Andresen, HG Russnes, SØ Fretland, RS Falk, OC Lingjærde, ... Journal of Translational Medicine 18, 1-10, 2020 | 44 | 2020 |
| Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation SK Chauhan, C Dunn, NK Andresen, AH Røssevold, G Skorstad, A Sike, ... NPJ Breast Cancer 10 (1), 30, 2024 | 4 | 2024 |
| Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors–a biomarker analysis of the ALICE and ICON trials NK Andresen, AH Røssevold, E Borgen, CB Schirmer, B Gilje, Ø Garred, ... Molecular Oncology, 2024 | 3 | 2024 |
| Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial NK Andresen, AH Røssevold, C Quaghebeur, B Gilje, B Boge, A Gombos, ... Journal for immunotherapy of cancer 12 (1), e007990, 2024 | 3 | 2024 |
| 215MO ICON–a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer JA Kyte, NK Andresen, C Quaghebeur, B Gilje, B Boge, A Gombos, ... Annals of Oncology 33, S636, 2022 | 3 | 2022 |
| Abstract PD11-11: PD11-11 Results from ALICE–Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase … JA Kyte, AH Røssevold, NK Andresen, CA Bjerre, B Gilje, EH Jakobsen, ... Cancer Research 83 (5_Supplement), PD11-11-PD11-11, 2023 | | 2023 |
| Gut microbiota diversity is prognostic and associated with benefit from chemo‐immunotherapy in metastatic triple‐negative breast cancer A Ullern, K Holm, AH Røssevold, NK Andresen, C Bang, OC Lingjærde, ... Molecular Oncology, 0 | | |
Jon Amund KyteOslo University hospitalEmail verificata su ous-hf.no
